Manuela Buonanno1, Veljko Grilj2, David J Brenner3. 1. Radiological Research Accelerator Facility (RARAF), New York, United States. Electronic address: mb3591@cumc.columbia.edu. 2. Radiological Research Accelerator Facility (RARAF), New York, United States. Electronic address: vg2400@cumc.columbia.edu. 3. Radiological Research Accelerator Facility (RARAF), New York, United States. Electronic address: djb3@cumc.columbia.edu.
Abstract
BACKGROUND: Radiotherapy outcomes are limited by toxicity in the healthy tissues surrounding the irradiated tumor. Recent pre-clinical studies have shown that irradiations with electrons or photons delivered at so called FLASH dose rates (i.e. >40 Gy/s) dramatically reduce adverse side effects in the normal tissues while being equally efficient for tumor control as irradiations at conventional dose rates (3-5 cGy/s). In the case of protons however, FLASH effects have not been investigated partially because of the limited availability of facilities that can achieve such high dose rates. METHODS: Using a novel irradiation platform, we measured acute and long-term biological effects in normal human lung fibroblasts (IMR90) exposed to therapeutically relevant doses of 4.5 MeV protons (LET = 10 keV/µm) delivered at dose rates spanning four orders of magnitude. Endpoints included clonogenic cell survival, γH2AX foci formation, induction of premature senescence (β-gal), and the expression of the pro-inflammatory marker TGFβ. RESULTS: Proton dose rate had no influence on the cell survival, but for the highest dose rate used (i.e. 1000 Gy/s) foci formation saturated beyond 10 Gy. In the progeny of irradiated cells, an increase in dose (20 Gy vs. 10 Gy) and dose rate (1000 Gy/s vs. 0.05 Gy/s) positively affected the number of senescence cells and the expression of TGFβ1. CONCLUSIONS: In normal lung fibroblasts proton dose rate had little impact on acute effects, but significantly influenced the expression of long-term biological responses in vitro. Compared to conventional dose rates, protons delivered at FLASH dose rates mitigated such delayed detrimental effects.
BACKGROUND: Radiotherapy outcomes are limited by toxicity in the healthy tissues surrounding the irradiated tumor. Recent pre-clinical studies have shown that irradiations with electrons or photons delivered at so called FLASH dose rates (i.e. >40 Gy/s) dramatically reduce adverse side effects in the normal tissues while being equally efficient for tumor control as irradiations at conventional dose rates (3-5 cGy/s). In the case of protons however, FLASH effects have not been investigated partially because of the limited availability of facilities that can achieve such high dose rates. METHODS: Using a novel irradiation platform, we measured acute and long-term biological effects in normal human lung fibroblasts (IMR90) exposed to therapeutically relevant doses of 4.5 MeV protons (LET = 10 keV/µm) delivered at dose rates spanning four orders of magnitude. Endpoints included clonogenic cell survival, γH2AX foci formation, induction of premature senescence (β-gal), and the expression of the pro-inflammatory marker TGFβ. RESULTS: Proton dose rate had no influence on the cell survival, but for the highest dose rate used (i.e. 1000 Gy/s) foci formation saturated beyond 10 Gy. In the progeny of irradiated cells, an increase in dose (20 Gy vs. 10 Gy) and dose rate (1000 Gy/s vs. 0.05 Gy/s) positively affected the number of senescence cells and the expression of TGFβ1. CONCLUSIONS: In normal lung fibroblasts proton dose rate had little impact on acute effects, but significantly influenced the expression of long-term biological responses in vitro. Compared to conventional dose rates, protons delivered at FLASH dose rates mitigated such delayed detrimental effects.
Authors: O Zlobinskaya; G Dollinger; D Michalski; V Hable; C Greubel; G Du; G Multhoff; B Röper; M Molls; T E Schmid Journal: Radiat Environ Biophys Date: 2012-01-07 Impact factor: 1.925
Authors: Hubert Y Pan; Jing Jiang; Karen E Hoffman; Chad Tang; Seungtaek L Choi; Quynh-Nhu Nguyen; Steven J Frank; Mitchell S Anscher; Ya-Chen Tina Shih; Benjamin D Smith Journal: J Clin Oncol Date: 2018-03-21 Impact factor: 44.544
Authors: T E Schmid; G Dollinger; V Hable; C Greubel; O Zlobinskaya; D Michalski; S Auer; A A Friedl; E Schmid; M Molls; B Röper Journal: Radiat Res Date: 2011-03-25 Impact factor: 2.841
Authors: O Zlobinskaya; C Siebenwirth; C Greubel; V Hable; R Hertenberger; N Humble; S Reinhardt; D Michalski; B Röper; G Multhoff; G Dollinger; J J Wilkens; T E Schmid Journal: Radiat Res Date: 2014-02-13 Impact factor: 2.841
Authors: Eric S Diffenderfer; Ioannis I Verginadis; Michele M Kim; Khayrullo Shoniyozov; Anastasia Velalopoulou; Denisa Goia; Mary Putt; Sarah Hagan; Stephen Avery; Kevin Teo; Wei Zou; Alexander Lin; Samuel Swisher-McClure; Cameron Koch; Ann R Kennedy; Andy Minn; Amit Maity; Theresa M Busch; Lei Dong; Costas Koumenis; James Metz; Keith A Cengel Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-01 Impact factor: 7.038
Authors: Neil G Burnet; Ranald I Mackay; Ed Smith; Amy L Chadwick; Gillian A Whitfield; David J Thomson; Matthew Lowe; Norman F Kirkby; Adrian M Crellin; Karen J Kirkby Journal: Br J Radiol Date: 2020-01-14 Impact factor: 3.039